首页|动脉粥样硬化性心血管疾病(ASCVD)的下一个管理靶点——抗炎治疗

动脉粥样硬化性心血管疾病(ASCVD)的下一个管理靶点——抗炎治疗

扫码查看
既往认为胆固醇是动脉粥样硬化性心血管疾病(ASCVD)的致病危险因素,随着研究的深入,ASCVD不再被认为是单纯的动脉壁脂质堆积疾病,而可能是一种进展性炎症反应.本文通过回顾冠状动脉抗炎策略的发展,明确了"炎症学说",复习小剂量秋水仙碱在冠心病应用的几个研究,进一步明确炎症治疗将为ASCVD的下一个管理靶点,管理炎症对降低心血管风险事件具有重要意义.
The Next Management Target of ASCVD-anti-inflammatory therapy
In the past,cholesterol was believed to be a pathogenic risk factor for ASCVD.With the deepening of research,ASCVD is no longer considered a simple arterial wall lipid accumulation disease,but may be a progressive inflammatory response.This article reviews the development of coronary artery anti-inflammatory strategies,clarifies the"inflammation theory",reviews several studies on the application of low-dose colchicine in coronary heart dis-ease,and further clarifies that inflammation treatment will be the next management target of ASCVD.Managing in-flammation is of great significance in reducing cardiovascular risk events.

InflammationReduce inflammationColchicineC-reactive proteinASCVD management targets

李丽鹃

展开 >

晋江市第二医院,福建泉州 362261

炎症 减少炎症 秋水仙碱 C反应蛋白 ASCVD管理靶点

2024

海峡药学
中国药学会福建分会

海峡药学

影响因子:0.643
ISSN:1006-3765
年,卷(期):2024.36(8)